Caliway Biopharmaceuticals Co (TPE:6919) Accounts Payable & Accrued Expense : NT$60.30 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Caliway Biopharmaceuticals Co Accounts Payable & Accrued Expense?

Caliway Biopharmaceuticals Co's quarterly accounts payable & accrued expense declined from Sep. 2024 (NT$50.98 Mil) to Dec. 2024 (NT$38.19 Mil) but then increased from Dec. 2024 (NT$38.19 Mil) to Mar. 2025 (NT$60.30 Mil).

Caliway Biopharmaceuticals Co's annual accounts payable & accrued expense increased from Dec. 2022 (NT$35.62 Mil) to Dec. 2023 (NT$64.04 Mil) but then declined from Dec. 2023 (NT$64.04 Mil) to Dec. 2024 (NT$38.19 Mil).

Caliway Biopharmaceuticals Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Caliway Biopharmaceuticals Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caliway Biopharmaceuticals Co Accounts Payable & Accrued Expense Chart

Caliway Biopharmaceuticals Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

45.88

31.30

35.62

64.04

38.19

Caliway Biopharmaceuticals Co Quarterly Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial									103.28	61.48	50.98	38.19	60.30

Caliway Biopharmaceuticals Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Caliway Biopharmaceuticals Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caliway Biopharmaceuticals Co Ltd (TPE:6919) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.99, Sec. 1, Xintai 5th Road, 32rd Floor-9, Xizhi District, New Taipei City, TWN, 221

Website

https://www.caliway.com.tw

Caliway Biopharmaceuticals Co Ltd specializes in the development of new drugs for aesthetic medicine and chronic inflammation. Its pipeline candidates are CBL-514, CBA-539, and CBO-012.

Caliway Biopharmaceuticals Co Headlines

No Headlines